Sanofi Wins Control of Genzyme

Feb. 16, 2011
Sanofi-Aventis will pay $20.1 billion for Genzyme

French pharmaceutical giant Sanofi-Aventis on Feb. 16 won control of giant U.S. biotechnology group Genzyme after increasing its offer considerably in a drawn out battle.

Sanofi-Aventis will pay $20.1 billion for Genzyme, with a further payment of $3.8 billion depending on how the U.S. company performs, the two companies said in a statement.

The two boards unanimously approved the deal and hope to close at the beginning of the second quarter, they said.

Sanofi-Aventis initially offered $18.5 million or $69 per share in October last year after talks on a tie-up with Genzyme made no progress.

At $20.1 billion, or $74 per share, the deal is second only to Roche's acquisition of another US firm, Genentech for $46.8 billion in 2009.

Copyright Agence France-Presse, 2011

Popular Sponsored Recommendations

How to Build Zero-Cost On-Site Solar and Storage Projects

Nov. 25, 2023
The Inflation Reduction Act offers tax credits, incentives, and financing that enable no-cost projects. In Enel’s eBook, discover the critical role that incentives play in your...

How Digital Twin Technology is Empowering Manufacturers

Sept. 27, 2023
This FAQ delves into why this technology offers business value and considerations toward implementation.

How Manufacturers Can Optimize Operations with Weather Intelligence

Nov. 2, 2023
The bad news? Severe weather has emerged as one of the biggest threats to continuity and safety in manufacturing. The good news? The intelligence solutions that build weather ...

Navigating Disruption: A Leader’s Guide to Strategy Under Uncertainty

Nov. 1, 2023
AI, sustainability, digital--industrials are facing disruptive forces that are redefining what it takes to win. What got your company where it is today won’t get you where you...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!